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Abstract 
Hormone-resistant prostate cancer (HRPC) occurs when prostate cancer is no longer 
responsive to hormone therapy. Treatment options are limited, and there is a clear necessity 
for therapies that improve outcome. Preclinical and clinical evidence supports the role of the 
immunomodulatory agent lenalidomide in HRPC. In this paper, we report that lenalidomide 
showed antitumoral activity in a patient with HRPC and bone metastases pre-treated with 
chemotherapy, decreased the PSA level and improved the patient’s health status for the first 
5 months. It is important to emphasize that it was not associated with hematologic toxicity. 
 
Introduction 
Prostate cancer is the most common cancer and the second leading cause of cancer 
death in men [1]. Androgen deprivation therapy is the treatment of choice in patients 
with advanced metastatic disease, although progression typically occurs within 1–2  
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years of initial response [2, 3]. Secondary hormonal therapy is an option in some 
patients; however, most neoplasms ultimately progress to a situation of androgen-
independent growth, namely hormone-resistant prostate cancer (HRPC), androgen-
independent prostate cancer or, recently, castration-resistant prostate cancer. 
Clinical manifestations include rising PSA (prostate serum antigen) concentration, 
bone metastases, substantive pain, and soft-tissue/lymph node metastases [4]. Some 
forms of HRPC treatment are systemic radiation therapy, chemotherapy, 
immunotherapy and estrogen therapy. However, outcomes in HRPC are very poor and 
therefore novel agents are needed to improve the treatment of this condition. Many 
approaches, such as drugs that target specific pathways involved in cell signaling, 
proliferation, apoptosis, immune modulation and angiogenesis, are currently under 
investigation to improve survival benefit. 
Lenalidomide is a thalidomide analog and also known as a member of the so-called 
immunomodulatory drugs (IMiDs) with immunomodulatory and antiangiogenic 
properties. In preclinical studies, lenalidomide demonstrated antitumoral activity, 
inhibiting hypoxia-induced factor-1α expression by endothelial cells and epithelial 
tumor cells, including prostate cells [5], and an increase in PC-3 prostate cancer cell 
apoptosis with monotherapy or in combination with docetaxel [6]. Using in vitro and in 
vivo models of prostate cancer, lenalidomide inhibited growth factor-induced invasion 
and produced synergistic effects in combination with docetaxel that slowed tumor 
progression [7]. The few published reports about the use of lenalidomide alone or in 
combination in HRPC patients [8–17] show clear evidence of its clinical antitumoral 
activity in this disease. In this paper, we demonstrate that lenalidomide not only has 
antitumoral activity but also has no associated hematologic toxicity. 
Case Report 
In this paper, we discuss the case of a 65-year-old male patient diagnosed in August 1999, by 
transurethral resection of the prostate, with a Gleason 6/10 prostate adenocarcinoma. His past 
medical history included renal clear cell adenocarcinoma of both kidneys and constipation treated 
with lactulose. The serum PSA at the time of diagnosis was elevated to 19.7 ng/ml (normal range 0.0–
4.0). Radiotherapy and combined androgen blockade (CAB) therapy was initiated, comprising lutein-
releasing hormone analog (Zoladex) and bicalutamide 50 mg daily (table 1). The patient remained 
asymptomatic with a low PSA level for 5 years (PSA nadir 0.1 ng/ml). In January 2008, biochemical 
and bone progression was diagnosed with an increased PSA of 12 ng/ml; bone metastases were 
detected by bone and CT scans. A similar scheme of hormonal therapy with CAB was administered. 
The patient was at castration testosterone levels (<50 ng/ml). However, 3 months later, his PSA rose 
again to 37 ng/ml. 
In April 2008, the patient was referred to our department with HRPC with bone-only metastases. 
The patient received a third hormonal therapy with cyproterone acetate for 2 months, but 
biochemical progression was detected with a new increase of PSA to 64 ng/ml. Subsequently, 
docetaxel-prednisone-based chemotherapy was started, but the patient’s PSA level rose again after an 
initial drop (64–12–38–57 ng/ml); bone and CT scans showed bone-only metastases. In October, 
second-line chemotherapy with oxaliplatin and capecitabine on a compassionate-use basis was 
administered, but after 3 cycles of treatment, PSA level was 233 ng/ml. In November 2008, this 
therapy was replaced by treatment with fulvestrant for compassionate use and, after the first month, 
PSA level returned to 32 ng/ml. However, in March 2009, his PSA value was higher than 300 ng/ml. 
Sunitinib was proposed for compassionate use. After being treated for 5 months with sunitinib (50 mg 
daily on days 1–4, given every 42 days), serum PSA level rose to 749 ng/ml. Soon thereafter, in August 
2009, the patient began treatment with vinblastine-Adriamycin-estramustine and ketoconazole,  
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which was discontinued after the third cycle given the clinical deterioration associated with more 
intense pain (initial PS 1; final PS 2) and increased levels of serum PSA (1,146 ng/ml). In October, the 
patient received antalgic radiotherapy for bone metastases. 
A new line of treatment with lenalidomide 25 mg/day for compassionate use together with 
analgesic agents was administered in November 2009. Concomitant analgesic medication for bone 
pain consisted of ibuprofen 600 mg/8 h, morphine sulfate 10 mg for rescue and fentanyl patches that 
were discontinued in January 2010. Hematological toxicity was assessed every 2 weeks and PSA 
monthly. The patient responded well to lenalidomide therapy, PSA level markedly declined to 391 
ng/ml and no hematological or cutaneous adverse events were documented; similar hemoglobin 
levels were maintained before and after lenalidomide treatment (10.4–11.7 g/dl). The patient 
regained the ability to walk over 7 km daily, maintaining his lifestyle, and he improved his general 
performance status until April 2010, when fentanyl patches were reintroduced and his PSA level rose 
to 422 ng/ml. In May 2010, an increased PSA level of 893 ng/ml was accompanied by clinical 
worsening due to the evolution of the disease, and therapy was suspended. 
After that, Estracyt (estramustine) 140 mg/12 h was started but no response was obtained; PSA 
level in July 2010 was >5,000 ng/ml, and bone and CT scans revealed lymph node, liver and lung 
metastases. The progressive deterioration of the patient’s health led to hospital admission and death 
in October 2010. 
Discussion 
Proliferation, angiogenesis and evasion of immune surveillance are important 
pathways by which HRPC progresses. Based on antiangiogenic and antitumoral 
properties of IMiDs, we may highlight thalidomide and lenalidomide among the new 
agents used for treating HRCP. It has been described that lenalidomide inhibits tumor 
necrosis factor-α production, diminishes levels of VEGF and basic fibroblast growth 
factor, stimulates T cells and hinders angiogenesis. It also promotes apoptosis in 
malignant cells. The antitumoral activity of lenalidomide is approximately 5,000 times 
more potent than thalidomide in animal models, and, furthermore, it has the additional 
advantage of being associated with a better toxicity profile. 
In fact, preliminary studies suggest that lenalidomide may have clinical activity in 
patients with metastatic castration-resistant prostate cancer [16, 17]. Nevertheless, 
published data about the use of lenalidomide in HRPC are rare so far, particularly in 
chemotherapy pre-treated patients. All of the data have shown clear evidence of 
antitumor activity of lenalidomide alone [13, 14] or in combination with docetaxel [9, 
12], paclitaxel [10, 15], ketoconazole [11] or GM-CSF [8] in metastatic HRPC patients. 
Responses described in these studies are promising with regard to survival advantage. 
According to our experience, the patient described here, pre-treated with 
chemotherapy, showed favorable response to lenalidomide therapy for 5 months – 
improving his general health status and quality of life, even discontinuing fentanyl 
administration for 4 months. It is significant to note that PSA levels declined, and 
disease response and pain reduction during lenalidomide administration was not 
accompanied by any toxicity. Hematological tests did not show alteration in 
hemoglobin levels, and the patient did not experience cutaneous adverse effects. This 
observation provides an additional benefit and suggests that lenalidomide may be an 
attractive drug because of its antineoplastic activity and low side effect profile. The 
evolution of the disease with the appearance of metastases led to worsening of the 
clinical situation of the patient.  
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The prognosis of prostate cancer is mainly determined by the presence or absence of 
metastases [18]. In our patient, the development of bone, lymph node, liver and lung 
metastases led to progressive deterioration, which is a common complication due to 
widespread disease expansion. 
Other treatments received by the patient mainly included subsequent lines of 
hormonal therapy, radiotherapy and chemotherapy with antineoplastic agents – 
standard treatments in the management of HRPC. Although reductions in PSA levels 
were achieved for a limited period of time, successive changes of therapy were 
required because of relapse and disease progression. 
Given the need for new agents that do not bear a potentially high cost in terms of 
side effects in the management of HRPC patients, lenalidomide is proposed as an 
interesting option. 
Conclusion 
In conclusion, the present case report presents new evidence of the potential of 
lenalidomide to provide clinical benefits to HRPC patients because of its antitumoral 
activity and lack of toxicity; the use of lenalidomide is supported in this patient 
population for delaying disease progression. 
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Table 1. Treatment and response 
                    Date  Prostate cancer 
treatment 
Initial PSA 
ng/ml 
Final PSA 
ng/ml 
Clinical observations 
                    Aug/99–Jan/08  RT/CAB  19.7  12  PSA nadir 0.1 ng/ml 
Bone metastases (CT) 
                    Jan/08–Apr/08  CAB  12  37  Castration testosterone levels 
                    Apr/08–Jun/08  Androcur  37  64  Bone metastases (CT) 
                    Jun/08–Aug/08  Taxotere/Pred  64  57  Bone metastases (CT) 
                    Oct/08–Nov/08  Oxi/Cap  57  233   
                    Nov/08–Mar/09  Fulvestrant  203  321  Bone metastases (CT) 
                    Mar/09–Aug/09  Sunitinib  321  749   
                    Aug/09–Sep/09  Vin/adri/estra/keto  749  1,146  Clinical deterioration 
Intense pain (final PS 2) 
                    Oct/09  Antalgic RT       Bone metastases (CT) 
                    Nov/09–May/10  Lenalidomide  1,146  893  Clinical improvement 
No hematologic toxicity 
                    May/10–Jul/10  Estracyt  1,146  >5,000  No response 
                    Oct/10        Lymph node, liver and lung 
metastases 
Progressive deterioration and 
death 
                    RT = Radiation therapy; CAB = combined androgen blockade therapy; Pred = prednisone; Oxi = 
oxaliplatin; Cap = capecitabine; Vin/adri/estra/keto = vinblastine-Adriamycin-estramustine-
ketoconazole. 
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